Allogene Therapeutics (ALLO) investor relations material

Executive summary

• Leadership transition with Zachary Roberts appointed CEO, emphasizing a patient-centric approach and strategic focus on allogeneic CAR T programs targeting cancer and autoimmune diseases.

• Core programs include ALPHA3 (cema-cel for LBCL), ALLO-316 (renal cell carcinoma), and ALLO-329 (autoimmune diseases), each showing clinical progress and differentiation.

• ALPHA3 pivotal Phase 2 trial is enrolling globally, with interim futility analysis showing strong MRD negativity and ctDNA reduction in cema-cel arm, supporting its potential as an outpatient, MRD-guided 1L consolidation therapy.

• FDA granted RMAT and Fast Track designations for cema-cel in ALPHA3 and for ALLO-316 in RCC, validating unmet need and program potential.

• Strong execution accelerated site activation, with ~100 ALPHA3 sites expected by year-end 2026, expanding access in both academic and community settings.

Financial highlights

• Q2 2026 net loss was $42.7 million, or $0.13 per share, improved from prior year; research and development expenses were $30.7 million, and general and administrative expenses were $20.8 million.

• Collaboration revenue for Q2 2026 was $4.6 million, recognized from the termination of the Overland license agreement.

• Cash, cash equivalents, and investments totaled $423.6 million as of June 30, 2026.

• Total assets were $550.1 million, liabilities $113.9 million, and stockholders' equity $436.2 million as of June 30, 2026.

• April 2026 public offering raised $187.9 million in net proceeds.

Outlook and guidance

• Cash runway expected to fund operations into Q1 2029, including proceeds from recent public offering.

• Enrollment for the randomized portion of ALPHA3 expected to complete by end of 2027, with interim EFS analysis in mid-2027 and primary analysis in mid-2028.

• Clinical and translational data update for ALLO-329 anticipated in Q4 2026.

• 2026 operating expense guidance is ~$165 million; GAAP operating expenses expected to be ~$225 million, including ~$35 million in non-cash stock-based compensation.

• Continued operational and regulatory updates planned as programs advance.